On 21 November, the PROMINENT consortium met in Stockholm and online for its third meeting to review progress, discuss Mid-Term Review feedback and plan the next phase. Project coordinator Linus Jönsson (Karolinska Institutet) restated the project’s objectives and summarised expert feedback, including calls for closer links with related Innovative Health Initiative projects and continued patient and carer involvement. The management team, represented by Anna Hansson (Karolinska Institutet) and Irene Lodoso (SYNAPSE Research Management Partners), reported on governance, internal communication and progress on amendments, deliverables and milestones. Technical updates from Xin Xia (Karolinska Institutet), Ferran Lugo (BarcelonaBeta Brain Research Center), Jyrki Lötjönen (Combinostics) and Linus Jönsson covered harmonising data sources, developing prediction models and diagnostic algorithms for Alzheimer’s disease and integrating them into the cNeuro-based digital platform, including a diagnostic tool to support more cost-effective diagnosis.
Ahead of the health economics session, Stefan de Vries (Amsterdam UMC) presented cMRI study results on diagnostic confidence, the impact of decision support on inter-reader agreement and atrophy ratings. Peter Lindgren (IHE – The Swedish Institute for Health Economics) and Matts Ekelund (BioArctic) gave an overview of real-world evidence work and preparations for pilot work with health technology assessment bodies. Further presentations by Lena Sannemann (Uniklinik Köln), Christophe Bintener and Ana Diaz (Alzheimer Europe) and Jyrki Lötjönen addressed evaluation studies, communication, Public Involvement and sustainability planning, including recruitment, visibility, the Public Involvement Board and long-term use of the platform and data. The meeting ended with inputs from Alina Solomon and Zunera Khan on related Innovative Health Initiative projects AD-RIDDLE and PREDICTOM and a discussion on synergies. In closing, Linus Jönsson thanked partners and reaffirmed the consortium’s commitment to delivering the digital platform, advancing studies and collaborating with other precision medicine projects.